Methoxyetomidate is an investigational anesthetic agent being developed by Jinzhou Ahon Pharmaceutical Co., Ltd. It is a short-acting intravenous anesthetic that acts as a positive allosteric modulator of GABAA receptors.[1][2] As of 2024, methoxyetomidate is undergoing Phase 3 clinical trials for use in anesthesia.[3][1]
Clinical data | |
---|---|
Other names | ET-26 |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
Chemical and physical data | |
Formula | C15H18N2O3 |
Molar mass | 274.320 g·mol−1 |
3D model (JSmol) | |
| |
|
References
edit- ^ a b "ET-26 Methoxyetomidate Hydrochloride Development Information". Synapse by Patsnap. Retrieved 2024-11-23.
- ^ Wang B, Chen S, Yang J, Yang L, Liu J, Zhang W (2017). "ET-26 hydrochloride (ET-26 HCl) has similar hemodynamic stability to that of etomidate in normal and uncontrolled hemorrhagic shock (UHS) rats". PLOS ONE. 12 (8): e0183439. Bibcode:2017PLoSO..1283439W. doi:10.1371/journal.pone.0183439. PMC 5557577. PMID 28813523.
- ^ "ET-26 Clinical Trials Overview". Synapse by Patsnap. Retrieved 2024-11-23.